Vitonnix
UK-developed preventive healthcare company producing sublingual nutritional sprays for health-conscious consumers.
Website: https://vitonnix.com/
Cover Block
Publicly reported
| Field | Value |
|---|---|
| Name | Vitonnix |
| Tagline | UK-developed preventive healthcare company producing sublingual nutritional sprays for health-conscious consumers. |
| Headquarters | London, UK [Dealroom.co] |
| Founded | 2014 [Dealroom.co] |
| Stage | Seed [Indian Startup News, October 2026] |
| Business model | Direct-to-Consumer (DTC) |
| Industry | Healthtech |
| Technology type | Biotech / Life Sciences |
| Geography | South Asia |
| Growth profile | Venture Scale |
| Founding team | Co-Founders (3+): Dr. Prashant Jindal, Dr. Deepti Jindal, Dr. Rajesh Handa [Indian Startup News, October 2026] |
| Funding label | Undisclosed [Indian Startup News, October 2026] |
Links
Publicly reported
- Website: https://vitonnix.com/
- Dr-Jindal: https://vitonnix.com/dr-jindal
- Collabs: https://vitonnix.com/collabs
Summary and Signal
PUBLIC Vitonnix makes sublingual nutritional sprays and merits attention now because it has just taken its first institutional seed capital, giving investors a fresh look at whether a doctor-led supplement brand can scale beyond marketplaces into broader retail and international distribution [Indian Startup News, October 2026] [VCCircle, October 2026]. The company was founded in 2014 and is described in public materials as a UK-developed preventive healthcare business, with research, formulation, and manufacturing based in India while global operations are reported to run from London and Birmingham [Dealroom.co, retrieved 2026] [Indian Startup News, October 2026].
Its core proposition is straightforward: use SubliSpray® sublingual delivery as an alternative to tablets, capsules, and gummies, with the company and related coverage asserting better bioavailability and faster absorption than conventional oral supplements, although those efficacy claims remain largely company-led rather than independently validated in the materials reviewed [UK Reporter, 2026] [vitonnix.com, retrieved 2024]. Public product listings and site copy show an existing range spanning categories such as multivitamins, vitamin D, biotin, melatonin, and B12, which suggests a broad consumer-wellness shelf strategy rather than a single-product wedge [vitonnix.com, retrieved 2024].
The founding team is the most legible part of the story at this stage. Public reporting identifies three doctor-founders, Dr. Prashant Jindal, Dr. Deepti Jindal, and Dr. Rajesh Handa, and LinkedIn corroborates Dr. Prashant Jindal's background as a refractive eye surgeon, which supports category credibility even if public evidence of prior consumer-brand operating experience is still thin [Indian Startup News, October 2026] [LinkedIn, retrieved 2026].
On financing, Vitonnix disclosed an undisclosed seed round in October 2026 led by Inflection Point Ventures, with participation from Riteish Deshmukh, Boman Irani, Jaspinder Narula, and Madhu Mantena, according to multiple Indian startup outlets [Indian Startup News, October 2026] [VCCircle, October 2026]. The commercial model appears to be DTC and marketplace-led, with public summaries referencing channels including Amazon, Flipkart, 1mg, and Blinkit, while Dealroom also reports a planned 2026 UK rollout of the first 10 products with Boots [Dealroom.co, retrieved 2026] [vitonnix.com, retrieved 2024].
Over the next 12 to 18 months, the key question is less whether consumers understand vitamins and more whether Vitonnix can convert formulation novelty into repeatable distribution, regulatory credibility, and brand retention across India and the UK [Indian Startup News, October 2026] [Dealroom.co, retrieved 2026]. Investors should watch for independent evidence on sell-through, retailer expansion, product-level repeat purchase, and whether the company's absorption claims are supported by data stronger than website positioning and partner coverage [vitonnix.com, retrieved 2024] [UK Reporter, 2026].
One source, partially checked -- Core funding details are corroborated by Indian Startup News and VCCircle, but product efficacy and several operating claims rely partly on company or partner materials.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Seed |
| Business Model | Direct-to-Consumer (DTC) |
| Industry / Vertical | Healthtech |
| Technology Type | Biotech / Life Sciences |
| Geography | South Asia |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
| Funding | Undisclosed |
Company Overview
PUBLIC
Vitonnix presents as a consumer health brand built around a specific delivery format rather than a broad wellness catalog. The company describes itself through its product surface, sublingual nutritional sprays, and its public materials place the business in London, with a 2014 founding date and a direct-to-consumer orientation [vitonnix.com, retrieved 2024].
The operating footprint appears split between the UK brand identity and Indian execution. Public reporting on Dealroom says research, formulation, and manufacturing are based in India, while global operations are run from London and Birmingham [Dealroom.co, retrieved 2026]. That matters because the company is positioning itself as UK-developed while building supply and commercialization capacity across India and, according to its site, selling through online commerce surfaces that include Tata 1mg product pages [vitonnix.com, retrieved 2024].
The clearest dated milestone in the public record is its first institutional seed round in October 2026, led by Inflection Point Ventures, with participation from Riteish Deshmukh, Boman Irani, Jaspinder Narula, and Madhu Mantena, according to named funding coverage [Indian Startup News, October 2026]. Separately, Dealroom reported that a UK rollout of an initial 10-product range with Boots was planned for 2026, which, if executed, would mark a move from marketplace-led distribution toward more formal retail placement [Dealroom.co, retrieved 2026].
One source, partially checked -- Confirmed in part by the company website and Dealroom, with the October 2026 financing corroborated by Indian Startup News.
The Product and the Stack
MIXED
What stands out first is not software complexity but delivery format. Vitonnix sells sublingual nutritional sprays, a consumer supplement product designed to deliver vitamins and related nutrients through the oral mucosa rather than through standard tablets or capsules [vitonnix.com, retrieved 2024] [UK Reporter, 2026]. Public materials describe the range as UK-developed SubliSpray® technology, while other coverage says research, formulation, and manufacturing are based in India and global operations are run from London and Birmingham [LinkedIn, retrieved 2026] [Dealroom.co, retrieved 2026]. That leaves a fairly clear public picture of the product architecture, even if the underlying IP position and manufacturing economics are not independently detailed in source material.
The consumer value proposition is framed around convenience and absorption. On its website, Vitonnix says its sprays are easier to consume than pills, pocket-friendly for on-the-go use, vegetarian, and free from artificial dyes, pigments, and fillers; it also claims "5X more effective than traditional oral supplements," a company statement that should be read as marketing language rather than independently verified clinical evidence [vitonnix.com, retrieved 2024]. External articles and category commentary cited in the research are directionally consistent on the broader mechanism, stating that sublingual delivery can improve bioavailability for some nutrients, particularly compared with conventional oral supplements, but those sources do not by themselves validate Vitonnix-specific performance claims [Express Healthcare, retrieved 2026] [mayabiotechindia, retrieved 2026] [ForMen Health, retrieved 2026].
The current product surface appears broad enough to support repeat consumer use, but the public evidence remains product-page level. Vitonnix's website lists sprays including biotin, melatonin, multivitamin, vitamin D, vitamin B12, energy, and veg omega variants, and third-party coverage says the company planned an initial range of 10 products, including a 2026 UK rollout with Boots [vitonnix.com, retrieved 2024] [Dealroom News] [Dealroom.co, retrieved 2026]. Claims that the company has filed patents for bottle designs and formulas, or that the products are pioneers of patented instant-absorption technology, are presently supported by company-adjacent or single-source reporting rather than by a cited patent database in the materials provided [Whalesbook] [Vitonnix Ltd. UK, retrieved 2026].
No independent source found -- This section relies heavily on company website claims and single-source product reporting, with limited independent corroboration beyond general category descriptions.
The Market They Are Entering
PUBLIC
The market matters now because Vitonnix sits at the intersection of preventive nutrition, consumer health ecommerce, and alternative supplement delivery formats, three areas where adoption can move quickly even when category definitions remain loose [Indian Startup News, October 2026] [VCCircle, October 2026].
The evidence base for a formal market size is thin. None of the captured third-party sources provide a named TAM, SAM, or SOM for sublingual nutritional sprays specifically, and the public reporting on Vitonnix focuses on fundraising and product positioning rather than category economics [Indian Startup News, October 2026] [Dealroom.co]. That leaves the cleaner reading as a qualitative one: Vitonnix appears to be pursuing a slice of the broader vitamins, minerals, and supplements market through a differentiated format, with current distribution oriented toward direct-to-consumer and marketplace channels rather than prescription care pathways [vitonnix.com, retrieved 2024] [Indian Startup News, October 2026].
Demand drivers are more visible than market size. Across the cited material, the recurring appeal is convenience plus absorption: Vitonnix and related category sources describe sublingual sprays as easier to consume than tablets and as a format that may improve bioavailability for some nutrients, especially in cases such as B12 where sublingual administration is commonly discussed as a faster route of absorption [vitonnix.com, retrieved 2024] [Boots UK Launches Innovative Vitonnix SubliSpray® Range - UK Reporter, 2026] [Oral Supplements vs. Sublingual Sprays - Which is More Effective?, retrieved 2026]. That matters commercially because convenience claims can support repeat consumer use even before a company proves deep clinical differentiation.
There is also a channel tailwind in the sources. The company is described as selling through ecommerce and marketplaces, including Amazon, Flipkart, 1mg, and Blinkit, which suggests Vitonnix is addressing a consumer purchase behavior already shaped by online health shopping rather than trying to build demand from scratch [PERPLEXITY SONAR PRO BRIEF] [vitonnix.com, retrieved 2024]. The planned UK rollout with Boots, as reported by Dealroom.co, points to a second route to market where discovery can shift from digital acquisition into retail shelf presence if the rollout proceeds as described [Dealroom.co].
The nearest adjacent markets are conventional oral supplements, gummies, and functional wellness products. Vitonnix's own positioning defines the substitute set clearly: tablets, capsules, and gummies are the baseline products it is trying to displace or complement with oral mucosa delivery [Boots UK Launches Innovative Vitonnix SubliSpray® Range - UK Reporter, 2026]. That is commercially useful because consumers already understand the underlying use case, but it also means the company is competing in a category where formulation credibility, brand trust, and distribution often matter as much as delivery mechanism.
Regulatory and macro forces cut both ways. On the positive side, preventive health spending and self-directed supplementation have remained durable themes in consumer health, which supports experimentation with new formats [Indian Startup News, October 2026]. The constraint is that the available sources do not establish any special regulatory clearance, clinical outcome dataset, or differentiated reimbursement pathway for Vitonnix, so the public case rests more on consumer adoption and retail execution than on a hard regulatory moat [Indian Startup News, October 2026] [VCCircle, October 2026].
| Market lens | Public evidence | Read-through for Vitonnix |
|---|---|---|
| Core category | Sublingual nutritional sprays positioned as an alternative to tablets, capsules, and gummies [Boots UK Launches Innovative Vitonnix SubliSpray® Range - UK Reporter, 2026] | Competes inside the broader supplements wallet rather than creating a wholly new need |
| Demand driver | Convenience and easier consumption versus pills [vitonnix.com, retrieved 2024] | Could help acquisition and repeat use in everyday wellness products |
| Functional claim | Enhanced bioavailability is repeatedly cited for sublingual delivery, though claim strength varies by source and nutrient [Boots UK Launches Innovative Vitonnix SubliSpray® Range - UK Reporter, 2026] [Oral Supplements vs. Sublingual Sprays - Which is More Effective?, retrieved 2026] | Supports premium positioning, but investors should separate category theory from company-specific proof |
| Channel structure | D2C and marketplaces are central; a UK Boots rollout is reported for 2026 [Indian Startup News, October 2026] [Dealroom.co] | Distribution breadth may matter as much as product science in early scaling |
The table shows a market defined less by published sizing data than by substitution dynamics. Public evidence supports a credible consumer wedge, but not yet a quantified claim on category share or market dominance.
One source, partially checked -- Section relies on named public reporting and company materials, but no independent third-party market sizing report was captured for the specific sublingual nutrition spray category.
The Competitive Field
MIXED Vitonnix is positioned less against a single named startup peer than against the broader supplement aisle, where conventional pills, capsules, gummies, and retailer-owned vitamin brands already control consumer attention and shelf space, while sublingual sprays try to win on convenience and absorption claims [vitonnix.com, retrieved 2024] [Boots UK Launches Innovative Vitonnix SubliSpray® Range - UK Reporter, 2026].
The competitive map is therefore easiest to read by segment rather than by venture roster. At the incumbent end, traditional oral supplements remain the reference product, because Vitonnix itself frames SubliSpray as an alternative to tablets, capsules, and gummies rather than as a new clinical category [Boots UK Launches Innovative Vitonnix SubliSpray® Range - UK Reporter, 2026]. Adjacent substitutes also matter. The company site highlights marketplace and retail surfaces including Tata 1mg, which suggests the real contest is for consumer purchase intent inside existing health-commerce channels, not only on a standalone DTC site [vitonnix.com, retrieved 2024].
Among challengers, the closest competitive set appears to be brands using spray-based or sublingual delivery, but the supplied research does not identify named startup rivals with enough source support to compare directly. That absence is itself informative. Public coverage around Vitonnix is still funding-led and product-led, not category-map-led, which usually means the brand has not yet been pulled into a widely documented leaderboard of venture-backed peers [Indian Startup News, October 2026] [VCCircle, October 2026]. In practice, consumers are still likely to benchmark Vitonnix against familiar vitamin formats first and novel spray formats second.
Where Vitonnix seems to have an edge today is distribution breadth and founder credibility, although both edges look perishable if not reinforced. Public materials show products associated with Tata 1mg on the company site, and separate reporting says a UK rollout of an initial 10 products with Boots is planned for 2026, which would give the company presence across Indian digital commerce and a recognized UK retail channel [vitonnix.com, retrieved 2024] [Dealroom.co, retrieved 2026]. The doctor-founded story is also central to its positioning. Available reporting identifies the founding team as Dr. Prashant Jindal, Dr. Deepti Jindal, and Dr. Rajesh Handa, with Dr. Prashant Jindal corroborated as a UK-based refractive eye surgeon [Indian Startup News, October 2026] [LinkedIn, retrieved 2026]. That can help with trust in a supplement category where formulation claims often blur together, but it is durable only if it converts into repeat purchase, retailer sell-through, or clinically credible substantiation that public sources do not yet show.
The company is more exposed on proof and channel ownership than on product storytelling. Most of the strongest differentiation claims, including superior absorption, instant absorption, and broad convenience advantages, come from company materials or category commentary rather than from disclosed Vitonnix-specific clinical evidence [vitonnix.com, retrieved 2024] [Vitonnix Ltd. UK, retrieved 2026] [Express Healthcare, retrieved 2026]. The seed round was also undisclosed in size, which limits confidence that the company can outspend larger supplement brands on paid acquisition if the category shifts into a CAC-heavy race for repeat DTC demand [Indian Startup News, October 2026] [VCCircle, October 2026]. Retail partners such as Boots or marketplace visibility on Tata 1mg can accelerate discovery, but those are channels the company does not fully own. Shelf placement, ranking, and repeat conversion remain vulnerable to stronger consumer brands and private-label alternatives.
The most plausible 18-month scenario is a distribution test rather than a winner-take-all breakout. If Boots execution lands on time and the initial 10-product range gets meaningful shelf rotation, Boots is the clearest winner if spray-format consumer adoption proves real at retail, because the retailer captures assortment advantage while validating the category for follow-on brands [Dealroom.co, retrieved 2026]. The most likely loser if that rollout underperforms is Vitonnix itself, not because the product thesis is disproven, but because the current public case rests heavily on access, formulation positioning, and founder credibility rather than on already-demonstrated scale economics or independently verified moat indicators [Indian Startup News, October 2026] [Dealroom News].
One source, partially checked -- This section relies on named public reporting for funding, founders, and planned distribution, but direct competitor identities and moat evidence are only partially substantiated in the supplied sources.
Opportunity
PUBLIC The prize here is not a niche supplements brand but a scaled consumer health platform that makes sublingual delivery a mainstream format for everyday micronutrition across India and selected international markets, if Vitonnix can convert early product differentiation and new institutional backing into repeat distribution wins [Indian Startup News, October 2026] [VCCircle, October 2026] [Dealroom.co].
The headline opportunity is straightforward. Vitonnix is trying to sell a simpler form factor for vitamins, one that it says delivers nutrients through a sublingual spray rather than traditional tablets or capsules [vitonnix.com, retrieved 2024] [UK Reporter, 2026]. That matters because the company already appears to have the basic ingredients required for a consumer-health scaling story: a doctor-founded brand identity, a distinct delivery format, evidence of marketplace distribution, and a first institutional seed round led by Inflection Point Ventures with named angel participants [Indian Startup News, October 2026] [VCCircle, October 2026]. If that combination holds, the reachable upside is a category leader in spray-based nutrition for mass-market consumers, not just a single-product wellness label.
The paths to scale are still few enough to state plainly.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| UK retail proof point | Vitonnix turns its planned UK launch into a retail credibility marker, then uses that to deepen trust and pricing power in India and other export markets | The reported 2026 Boots rollout for its first 10 products [Dealroom.co] | A credible pharmacy partner can validate merchandising and consumer demand for an unfamiliar format, and Vitonnix has already been described as UK-developed with operations run from London and Birmingham [Dealroom.co] [LinkedIn, retrieved 2026] |
| India omnichannel nutrition brand | The company expands from D2C and marketplaces into a broader omnichannel wellness brand with repeat-buy SKUs across energy, multivitamin, melatonin, vitamin D, and other daily-use categories | Fresh seed capital earmarked for consumer growth, leadership, distribution, and international expansion [Indian Startup News, October 2026] [VCCircle, October 2026] | The product range visible on the company site already spans multiple routine-use supplement categories, and management has signaled a 10-product range rather than a single hero SKU [vitonnix.com, retrieved 2024] [Dealroom News] |
| Format leader in preventive health | Vitonnix becomes the reference brand for sublingual spray supplementation if consumer education around absorption and convenience shifts the category toward sprays | Wider acceptance of sublingual delivery as an alternative to pills and gummies [UK Reporter, 2026] [Express Healthcare] | Multiple cited sources, including third-party coverage, describe sublingual delivery as offering improved bioavailability or faster absorption for some nutrients, especially B12, which supports the format-level thesis even if brand-level proof is still early [UK Reporter, 2026] [Oral Supplements vs. Sublingual Sprays - Which is More Effective?] |
The compounding mechanism would come from distribution and format familiarity rather than from a classic software network effect. A consumer who adopts one daily spray can be sold adjacent SKUs in the same regimen, and the company site already shows a portfolio that spans multivitamin, vitamin D, biotin, melatonin, B12, and energy positioning [vitonnix.com, retrieved 2024]. If repeat purchase behavior is healthy, each additional SKU can lower blended customer acquisition burden by raising lifetime value, while broader retail or marketplace presence can make the spray format feel normal rather than experimental. The early signs are modest but visible: reported marketplace presence, a dedicated growth hiring motion, and financing explicitly tied to consumer growth and distribution expansion [Indian Startup News, October 2026] [VCCircle, October 2026].
The size of the win is harder to anchor because no reliable market-size dataset or direct public comparable is present in the cited material. The cleaner way to frame it is conditional. If Vitonnix were to establish itself as one of the leading branded nutrition-spray companies across India and the UK, with broad retail placement and a defensible repeat-purchase engine, the business could support venture-scale outcomes through strategic acquisition or later-stage growth financing, particularly because the current round is being positioned as its first institutional capital rather than a fully matured consumer brand story [Indian Startup News, October 2026] [Dealroom News]. That is a scenario, not a forecast, and the gap between current public evidence and that outcome remains wide. But the upside case is real enough to watch closely because the company is not inventing demand from zero, it is trying to shift consumers into a potentially more convenient delivery format within an existing, high-frequency health spend category [vitonnix.com, retrieved 2024] [UK Reporter, 2026].
One source, partially checked -- This section relies on named-publisher funding coverage and public company materials, but several core product-performance and rollout claims remain only partially corroborated by company or single-source reporting.
Sources
Publicly reported
[Indian Startup News, October 2026] Healthcare startup Vitonnix raises first institutional investment from Inflection Point Ventures, others | https://indianstartupnews.com/funding/healthcare-startup-vitonnix-raises-first-institutional-investment-from-inflection-point-ventures-others-12684703
[VCCircle, October 2026] Shamrock AI, AdGraam, Formial Labs, Vitonnix bag early-stage cheques | https://www.vccircle.com/shamrockai-adgraam-formial-labs-vitonnix-bag-early-stage-cheques
[Dealroom.co] Vitonnix raises first institutional seed round led by Inflection Point Ventures | https://app.dealroom.co/news/feed/vitonnix-raises-first-institutional-seed-round-led-by-inflection-point-ventures
[Dealroom.co, retrieved 2026] Vitonnix raises first institutional seed round led by Inflection Point Ventures | https://app.dealroom.co/news/feed/vitonnix-raises-first-institutional-seed-round-led-by-inflection-point-ventures
[vitonnix.com, retrieved 2024] Nutritional Health Supplements | Vitonnix Sublingual Sprays | https://vitonnix.com/
[LinkedIn, retrieved 2026] Dr Prashant Jindal - London, England, United Kingdom | Professional Profile | LinkedIn | https://www.linkedin.com/in/drprashantjindal/
[LinkedIn, retrieved 2026] Sachin Chauhan - The White Coat Network | LinkedIn | https://www.linkedin.com/in/sachin-chauhan-421721b2/
[Dealroom News] Vitonnix lands first institutional capital in seed round led by Inflection Point Ventures | Dealroom News | https://dealroom.co/news/163395-vitonnix-lands-first-institutional-capital-in-seed-round-led-by-inflecti/
[Whalesbook] Vitonnix Raises Seed Funding Led by IPV for Global Expansion | Whalesbook | https://www.whalesbook.com/news/English/startupsvc/Vitonnix-Raises-Seed-Funding-Led-by-IPV-for-Global-Expansion/6ad3529579a16deaeaf53cf2
Articles about Vitonnix
- A Doctor-Founded Startup Puts Vitamins Under the Tongue — The UK-India startup, founded by three physicians, is using its first institutional funding to expand beyond DTC marketplaces and into UK retail.